IXEKIZUMAB achieved high clinical response rates in children with juvenile idiopathic arthritis in a Phase III trial.
Ixekizumab in Juvenile Idiopathic Arthritis
Juvenile psoriatic arthritis and enthesitis-related arthritis are recognized categories of juvenile idiopathic arthritis that can be difficult to control despite available therapies. Current treatment options include nonsteroidal anti-inflammatory drugs, glucocorticoids, conventional synthetic disease modifying antirheumatic drugs, and biologic disease modifying therapies. However, a substantial proportion of patients do not achieve sustained clinical remission.
The COSPIRIT-JIA trial evaluated the efficacy and safety of ixekizumab in children with active enthesitis-related arthritis and juvenile psoriatic arthritis who were candidates for biologic therapy. The multicenter Phase III study used an open label design with a randomized reference group receiving adalimumab. Children aged 6 to younger than 18 years with enthesitis related arthritis and those aged 2 to younger than 18 years with juvenile psoriatic arthritis were eligible if they had at least 3 active peripheral joints and a body weight of 10 kg or greater.
Participants received subcutaneous ixekizumab or adalimumab using weight-based dosing schedules. Ixekizumab was administered every 4 weeks after an initial dose, while adalimumab was given every 2 weeks. The primary endpoint measured the proportion of patients achieving a JIA American College of Rheumatology 30 (ACR30) response at week 16, defined as at least 30% improvement across core disease activity measures.
High Clinical Response Rates Observed
The trial enrolled 101 participants between April 2021 and April 2024. Eighty-one received ixekizumab and 20 received adalimumab as a reference group. Among patients treated with ixekizumab, 60 were biologic disease modifying therapy naïve and 21 had prior biologic exposure.
At week 16, JIA ACR30 response rates were high in the ixekizumab group. Ninety-percent of biologic-naïve participants achieved the response criteria, while 86% of biologic experienced participants also met the endpoint. These findings suggest that ixekizumab can produce clinically meaningful improvement in both treatment naive and previously treated pediatric patients.
Safety Profile Consistent with Previous Indications
Treatment emergent adverse events in the ixekizumab group were mostly mild or moderate. Half were classified as mild and just over one-third as moderate, with no severe treatment emergent adverse events reported. Investigators noted that the observed safety profile was consistent with that seen in adult psoriatic arthritis and spondyloarthritis as well as pediatric psoriasis indications.
The investigators concluded that ixekizumab was effective and well tolerated for children with enthesitis related arthritis and juvenile psoriatic arthritis who require biologic disease modifying therapy.
Reference
Ramanan A V et al. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. The Lancet Rheumatology. 2025:S2665-9913(25)00346-7. Epub ahead of print.
Featured Image: zinkevych on Adobe Stock.
